Literature DB >> 36225639

Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Wanying Liu1, Qingqing Cai2, Tiantian Yu1, Paolo Strati3, Frederick B Hagemeister3, Qiongli Zhai4, Mingzhi Zhang5, Ling Li5, Xiaosheng Fang6, Jianyong Li7, Ruifang Sun8, Shanxiang Zhang9, Hanjin Yang10, Zhaoming Wang10, Wenbian Qian11, Noriko Iwaki12, Yasuharu Sato13, Eric Oksenhendler14, Zijun Y Xu-Monette15, Ken H Young15,16, Li Yu1.   

Abstract

Castleman disease (CD) has been reported as a group of poorly understood lymphoproliferative disorders, including unicentric CD (UCD) and idiopathic multicentric CD (iMCD) which are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative. The clinical and independent prognostic factors of CD remain poorly elucidated. We retrospectively collected the clinical information of 428 patients with HIV and HHV-8 negative CD from 12 large medical centers with 15-year follow-up. We analyzed the clinicopathologic features of 428 patients (248 with UCD and 180 with iMCD) with a median age of 41 years. The histology subtypes were hyaline-vascular (HV) histopathology for 215 patients (56.58%) and plasmacytic (PC) histopathology for 165 patients (43.42%). Most patients with UCD underwent surgical excision, whereas the treatment strategies of patients with iMCD were heterogeneous. The outcome for patients with UCD was better than that for patients with iMCD, 5-year overall survival (OS) rates were 95% and 74%, respectively. In further analysis, a multivariate analysis using a Cox regression model revealed that PC subtype, hepatomegaly and/or splenomegaly, hemoglobin ≤ 80 g/L, and albumin ≤ 30 g/L were independent prognostic factors of CD for OS. The model of iMCD revealed that age > 60 years, hepatomegaly and/or splenomegaly, and hemoglobin ≤ 80 g/L were independent risk factors. In UCD, single-factor analysis identified two significant risk factors: hemoglobin ≤ 100 g/L and albumin ≤ 30 g/L. Our study emphasizes the distinction of clinical characteristics between UCD and iMCD. The importance of poor risk factors of different clinical classifications may direct more precise and appropriate treatment strategies. AJCR
Copyright © 2022.

Entities:  

Keywords:  Castleman disease; clinical characteristics; risk prognostic factors; treatment

Year:  2022        PMID: 36225639      PMCID: PMC9548017     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   5.942


  32 in total

1.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

Review 2.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

3.  Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor.

Authors:  Yujun Dong; Mingyue Wang; Lin Nong; Lihong Wang; Xinan Cen; Wei Liu; Sainan Zhu; Yuhua Sun; Zeyin Liang; Yuan Li; Jinping Ou; Zhixiang Qiu; Hanyun Ren
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

4.  A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

Authors:  Li Yu; Menghan Shi; Qingqing Cai; Paolo Strati; Fredrick Hagemeister; Qiongli Zhai; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbin Qian; Noriko Iwaki; Yasuharu Sato; Lu Zhang; Jian Li; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young
Journal:  Oncologist       Date:  2020-09-18

Review 5.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

6.  Targeting the mTOR pathway in idiopathic multicentric Castleman disease.

Authors:  Robert M Stern; Nancy Berliner
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

7.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

8.  Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience.

Authors:  Seyoung Seo; Changhoon Yoo; Dok Hyun Yoon; Shin Kim; Jung Sun Park; Chan-Sik Park; Jooryung Huh; Cheolwon Suh
Journal:  Blood Res       Date:  2014-12-23

Review 9.  Translating IL-6 biology into effective treatments.

Authors:  Ernest H Choy; Fabrizio De Benedetti; Tsutomu Takeuchi; Misato Hashizume; Markus R John; Tadamitsu Kishimoto
Journal:  Nat Rev Rheumatol       Date:  2020-04-23       Impact factor: 20.543

10.  Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease: renal function is an important prognostic factor.

Authors:  Lu Zhang; Zhiyuan Li; Xinxin Cao; Jun Feng; Dingrong Zhong; Shujie Wang; Daobin Zhou; Jian Li
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.